Potentially Inappropriate Medications Use among Older Adults with Comorbid Diabetes and Hypertension

CURRENT STATUS: UNDER REVIEW

Monira Alwhaibi  malwhaibi@ksu.edu.sa
Corresponding Author

DOI:
10.21203/rs.2.20969/v1

SUBJECT AREAS
Geriatrics & Gerontology

KEYWORDS
Beers Criteria, Diabetes, Elderly, Hypertension, Inappropriate Prescribing
Abstract

Background Potentially inappropriate medications (PIMs) are medications that should be avoided among older adults due to their risk which offsets their benefit. The objective of this study is to estimate the prevalence of PIMs use and to evaluate its associated factors among older adults with comorbid diabetes and hypertension using the 2019 Beers criteria.

Methods A cross-sectional retrospective study design was used. This study included 1,853 older adults (age ≥ 65 years) with comorbid diabetes and hypertension visited an ambulatory care setting in a large hospital in the central region of Saudi Arabia. The primary outcome was the prevalence of PIMs use based on the updated 2019 American Geriatric Society (AGS) Beers Criteria. The secondary outcome was the factors associated with the presence of PIMs use (use of one or more PIMs) by referencing the Beers Criteria list.

Results Almost one out of two individuals had PIMs use with the average number of medication taken was seven; where 40.3% of the older adults taken one PIMs, and about 16% were using two or more PIMs. The most commonly prescribed PIMs were the use of gastrointestinal and endocrine medications. High risk of PIMs use was among those with ischemic heart disease and anxiety comorbidities and those using multiple medications (i.e., polypharmacy).

Conclusions Given higher PIMs use among older adults with diabetes and hypertension comorbidities, tailored strategies and interventions to minimize the PIMs use in this population are warranted. There is a need for greater vigilance when managing patients with comorbid conditions to avoid the use of inappropriate medications.

Background
Comorbid chronic conditions among older adults population presented many challenges to the healthcare system given the growing prevalence and burden of chronic illnesses. The coexistence of two or more chronic conditions, also known as multimorbidity, is very common among older adults [1]. The most common disease cluster is diabetes and hypertension [2]; approximately two-thirds of adults with diabetes have hypertension comorbidity [3]. Managing older adults with multiple chronic diseases is much more complicated than managing those with a single condition. Which might result in a complex treatment regime, in terms of drug-disease interactions [4]. Clinical guidelines have been developed to describe standards of care to improve quality of healthcare. However, most clinical guidelines focus on single diseases and do not always provide management for individuals with comorbidities [5]. Therefore, older adults with comorbidities are at a greater risk of potentially inappropriate medications use due to the use of multiple medications to manage their chronic conditions. Potentially inappropriate medications (PIMs) are medications that should be avoided among older adults due to their risk which offsets their benefit. Beers criteria are commonly used to identify PIMs, the latest update was in 2019 [6]. Approximately one-third of older adults prescribed at least one potentially inappropriate medication [7–9]. PIMs use imposes a higher risk of hospital admission, adverse drug events, and other negative health outcomes [10–14]. Besides, PIMs use is associated with an economic burden on the patient, payer, and healthcare system [7, 15]. This can be amplified in older adults with comorbid diabetes and hypertension which are one of the top expensive health conditions [16], and a great economic burden exists when these conditions are comorbid [17].

Despite the growing body of research that has been done among older adults to identify PIMs use, insight into the PIMs use among specific disease clusters is limited. Thus,
identifying PIMs use among older adults with comorbidities can provide effective tools in the clinical setting to identify individuals who are at higher risk than others. Likewise, the PIMs identification can improve the understanding of the prevalence and risk factors of PIMs use among older adults with comorbidities and develop strategies for avoiding and limiting the burdens of inappropriate medications. Recent years have witnessed a wide use of the real-world data, the electronic health records (EHRs), to conduct research and answer practical questions that help healthcare providers and policymakers to make informed health care decisions. Using the EHRs, a comprehensive source of inpatient and outpatient health records, the main purpose of this study was to identify the of PIMs use among older adults focusing on diabetes and hypertension comorbidity. These comorbidities are selected as they are the most common disease clusters and impose a higher burden on patients, payers, and the healthcare system.

Methods

Study Design

A cross-sectional retrospective study design was conducted. The study was approved by the institutional review board under protocol number (E-17-2580).

Data Source

This study had used data from the electronic health records database. The Institutional Review Board (IRB) was obtained. Data collected included patient’s age, gender, marital status, nationality, prescribed medications, and diagnosed chronic conditions (using the International Classifications of Diseases – 9th edition, Clinical Modification (ICD-9-CM) codes).

Study Population and setting

Older patients, aged 65 years and older, with clinical diagnosis of both diabetes and
hypertension were identified over a one year period from the EHRs and included in this study. The study was conducted among patients who received their care from ambulatory care setting in a large hospital in the central region of Saudi Arabia. This hospital provide health services with no cost to Saudi citizens who are mostly residents in Riyadh, the capital city, and also serves as a referral center for the whole country.

Measurements

The updated 2019 American Geriatric Society (AGS) Beers Criteria was used to identify PIMs use [6]. This study identified the presence of PIMs use (use of one or more PIMs) by referencing the Beers Criteria list. PIMs use was further classified into (one, two, and three or more PIMs). Demographic variables included age, gender, nationality, and marital status. Information about the diagnosed chronic health conditions was identified using the ICD-9-CM codes. This study identified the following chronic conditions: dyslipidemia, ischemic heart disease (IHD); asthma, osteoarthritis and osteoporosis, and anxiety. These conditions were selected as they are highly prevalent among older adults with diabetes and hypertension. Polypharmacy use among older adults was also measured and measured as the use of five or more medications.

Statistical Analysis

Descriptive and inferential statistics were used to identify the prevalence and associated factors of PIMs use in older adults. Chi-square tests, bivariate analysis, were used to assess the difference between older adults with and without PIMs in regards to sociodemographic and clinical characteristics. All factors with a probability value of < 0.05 were included in the regression analysis. Binary logistic regression was used to examine the factors associated with a higher likelihood of PIMs use. All statistical tests were
performed using the Statistical Analysis Software, version 9.2 (SAS Institute Inc., Cary, NC).

Results

Table 1 displays the demographic characteristics and health conditions of the study population. There were 1,853 older adults (age ≥ 65 year) with comorbid diabetes and hypertension with an average age of seventy-two. Approximately 62% of the study population was women and the average number of diagnosed coexisting chronic conditions being three. Nearly 64%, 11%, 10%, 7% of the study population were diagnosed with dyslipidemia, asthma, osteoarthritis, and anxiety, respectively.

Findings of this study indicate that PIMs use occurred in 56% of older adults with comorbid diabetes and hypertension (Table 2). In addition, 40%, 13%, and 3% were prescribed one, two, and three or more PIMs, respectively. The most common PIMs use was gastrointestinal medications (54%), followed by endocrine agents (28%). The use of PIMs was significantly higher among those with IHD, anxiety disorder and those who were taking five or more medications (i.e., polypharmacy) (p < .0001). Older adults who were taking five or more medications were more likely to have PIMs use (adjusted odds ratio (AOR) = 4.14; confidence interval (CI): 3.06-5.60; p < 0.001) compared to those with four or fewer medications (Table 3). PIMs use was more likely among older adults with comorbid IHD (AOR = 2.12; CI: 1.35-3.32; p < 0.001) and anxiety (AOR = 3.08; CI: 1.87-5.07; p < 0.001) compared to older adults without these comorbidities.

Discussion

This study found that the higher use of potentially inappropriate medications among older adults with comorbid diabetes and hypertension when safer alternatives exist. This population is most vulnerable as they suffer from other coexisting chronic conditions and
take multiple medications to manage these conditions.

The updated 2019 Beers criterion were used to examine PIMs use. Findings from this study indicate that one out of two older adults with comorbid diabetes and hypertension are taking at least one inappropriate medication. Bazargan et al. in their cross-sectional study among 193 older adults with hypertension have found that one out of two participants had inappropriate medication use [18]. Published studies among older adults from the outpatient setting reported a lower rate, about one-third of older adults are prescribed of PIMs [7–9]. The rate of PIMs use in this study is considerably higher than the previously reported PIMs use among older adults. The higher rate of PIMs use may reflect the fact that this study focused on older adults with the most common disease cluster, diabetes and hypertension. These comorbidities usually require the use of multiple medications to manage their conditions. It has to be noticed that a commonly prescribed PIMs in the present study was the use of endocrine agents. Given that several drugs to manage diabetes are listed in Beers’ criteria, it was not surprising to find a higher rate of inappropriate endocrine medications uses which should be avoided due to the increased risk of hypoglycemia. Other commonly prescribed PIMs were the use of gastrointestinal agents that include mainly proton pump inhibitors (PPIs). Studies examining PIMs use among older patients also documented a higher rate of inappropriate use of PPIs common among older adults [7, 18, 19]. Healthcare providers should carefully monitor the duration of the use of PPIs in older adults except for high-risk patients (e.g., chronic NSAID use) as recommended by the AGS. Besides, it is important that healthcare providers avoid prescribing potentially inappropriate endocrine medications listed as PIMs, and be aware of the Beer’s criteria list. A systematic review of twenty-two published studies has shown that one of the barriers for prescribers to stop PIMs include the knowledge gap and lake of awareness about stopping or changing PIMs [20]. Coexisting chronic conditions were
important factors for PIMs use. Seventy percent of the present study population who had
dyslipidemia uses at least one PIM. Further, individuals with anxiety and IHD are more
likely to use PIMs. Anxiety disorder has been identified as a predictor of PIMs use in other
published studies [9, 21]. One of the most likely factors associated with PIMs use in this
study was the use of five or more medications. Indeed, it is not surprising that using
multiple medications leads to PIMs use. This is consistent with many studies that reported
a higher likelihood to use PIMs among older adults using multiple medications [9, 22].

Multiple practical implications can emanate from the present study findings. The findings
can be used to alert prescribers to the potential for improving prescribing in this
vulnerable population. Endocrinologists and primary care healthcare providers need to
provide routine screening for older adults mainly for those who are taking multiple
medications. These screenings can detect PIMs early, thereby preventing the subsequent
negative health consequences of inappropriate medications. Wang-Hansen et al. in their
study among 232 acutely hospitalized older adults with multimorbidity in a Norwegian
regional hospital found that 44% of the serious adverse drug events could have been
prevented by adherence to the Screening tool for PIMs [23]. Further, stakeholders can
incorporation Beers criteria as an indicator to evaluate the quality of prescribing in older
adults and support the need for medication therapy management service to older adults
with diabetes. There is also a need for increasing awareness of healthcare providers of the
PIMs that should be avoided by older adults, especially those taking care of patients with
diabetes and hypertension.

Findings of this study highlighted that the 2019 AGS Beers criteria provide a valuable
guide for improving quality of care for older adults. Given higher PIMs use among older
adults with diabetes and hypertension comorbidities, tailored strategies and interventions
to reduce the PIMs use in this population are warranted. There is a need for greater
vigilance when managing patients with comorbid conditions to avoid the use of inappropriate medications. Medication review and management are important interventions as PIMs use and polypharmacy are connected and both are linked to poor health outcomes among older adults. With the projected growth of the rate of diabetes and hypertension, strategies to minimize the use of avoidable medications among this population are needed.

**Strengths and Limitations**

The uniqueness of this study is evaluating the factors affecting PIMs use among older patients with diabetes and hypertension comorbidities, a vulnerable population. Using electronic health records enabled us to use a large sample size and comprehensive data to identify the prescribed PIMs. Therefore, this study provides more understanding of the unnecessary use of PIMs and provides a knowledge base for stakeholders to minimize medications risk. Accordingly, this study addresses important information to policymakers about a serious of the problem of the PIMs use to take a lead in providing effective interventions such as medication therapy management (MTM) service and proper diabetic care to reduce the use of PIMs. However, this study has some limitations. First, the findings of this study cannot be generalized to all older adults with comorbid diabetes and hypertension entirely as this study was conducted in a single setting in Saudi Arabia. Second, the unmeasured confounders such as the severity of chronic conditions, patients’ beliefs and attitudes, prescriber and healthcare system factors are not available in the EHRs and were not adjusted in the analysis. Besides, given the nature of the study design, a causal relationship cannot be identified.

**Declarations**
Ethics approval and consent to participate

A secondary database “the Medical Expenditure Panel Survey (MEPS) database” a publically available database was used, therefore no ethical approval or consent to participate is required.

Consent for publication

Not applicable.

Availability of data and materials

The dataset supporting the conclusions of this article is available from the Medical Expenditure Panel Survey (MEPS) database, and openly made available for researchers at the following website: https://meps.ahrq.gov/data_stats/download_data_files.jsp.

Competing interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Authors’ Contributions

Dr. Monira Alwhaibi has participated in designing the study, drafting the manuscript, analysis, interpretation of the findings, revising the manuscript content and gave final approval of the final version of this manuscript.

Acknowledgment

This research project was supported by a grant from the “Research Center of the Center for Female Scientific and Medical Colleges”, Deanship of Scientific Research, King Saud
University.

References

1. Pefoyo AJK, Bronskill SE, Gruneir A, Calzavara A, Thavorn K, Petrosyan Y, et al. The increasing burden and complexity of multimorbidity. BMC Public Health. 2015;15:415.
2. Sinnige J, Braspennsing J, Schellevis F, Stirbu-Wagner I, Westert G, Korevaar J. The prevalence of disease clusters in older adults with multiple chronic diseases—a systematic literature review. PloS one. 2013;8:e79641.
3. Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. The journal of clinical hypertension. 2011;13:244–51.
4. Fabbri E, Zoli M, Gonzalez-Freire M, Salive ME, Studenski SA, Ferrucci L. Aging and multimorbidity: new tasks, priorities, and frontiers for integrated gerontological and clinical research. J Am Med Dir Assoc. 2015;16:640–7.
5. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. Jama. 2005;294:716–24.
6. Panel AGSBCUE, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67:674–94.
7. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 2010;69:543–52.
8. Bruin-Huisman L, Abu-Hanna A, van Weert HC, Beers E. Potentially inappropriate prescribing to older patients in primary care in the Netherlands: a retrospective longitudinal study. Age Ageing. 2017;46:614–9.
9. Alhawassi TM, Alatawi W, Alwhaibi M. Prevalence of potentially inappropriate medications use among older adults and risk factors using the 2015 American Geriatrics Society Beers criteria. BMC Geriatr. 2019;19:154.
10. Fick DM, Mion LC, Beers MH, Waller L. J. Health outcomes associated with potentially inappropriate medication use in older adults. Res Nurs Health. 2008;31:42–51.
11. Pérez T, Moriarty F, Wallace E, McDowell R, Redmond P, Fahey T. Prevalence of potentially inappropriate prescribing in older people in primary care and its association with hospital admission: longitudinal study. bmj. 2018;363:k4524.
Reich O, Rosemann T, Rapold R, Blozik E, Senn O. Potentially inappropriate medication use in older patients in Swiss managed care plans: prevalence, determinants and association with hospitalization. PLoS one. 2014;9:e105425.

13. Lund BC, Carnahan RM, Egge JA, Chrischilles EA, Kaboli PJ. Inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother. 2010;44:957–63.

14. Xing XX, Zhu C, Liang HY, Wang K, Chu YQ, Zhao LB, et al. Associations Between Potentially Inappropriate Medications and Adverse Health Outcomes in the Elderly: A Systematic Review and Meta-analysis. Ann Pharmacother. 2019;53:1005–19.

15. Fick D. Potentially inappropriate medication use in a Medicare managed care population: association with higher costs and utilization. Journal of Managed Care Pharmacy. 2001;7:407–13.

16. Druss BG, Marcus SC, Olfson M, Pincus HA. The most expensive medical conditions in America. Health Aff. 2002;21:105–11.

17. Wang G, Zhou X, Zhuo X, Zhang P. Annual total medical expenditures associated with hypertension by diabetes status in US adults. Am J Prev Med. 2017;53:182-S9.

18. Bazargan M, Smith JL, King EO. Potentially inappropriate medication use among hypertensive older African-American adults. BMC Geriatr. 2018;18:238.

19. Bala SS, Narayan SW, Nishtala PS. Potentially inappropriate medications in community-dwelling older adults undertaken as a comprehensive geriatric risk assessment. Eur J Clin Pharmacol. 2018;74:645–53.

20. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ open. 2014;4:e006544.

21. Masumoto S, Sato M, Maeno T, Ichinohe Y, Maeno T. Association between potentially inappropriate medications and anxiety in Japanese older patients. Geriatr Gerontol Int. 2017;17:2520–6.

22. Buck MD, Atreja A, Brunker CP, Jain A, Suh TT, Palmer RM, et al. Potentially inappropriate medication prescribing in outpatient practices: prevalence and patient characteristics based on electronic health records. Am J Geriatr Pharmacother. 2009;7:84–92.

23. Wang-Hansen MS, Wyller TB, Hvidsten LT, Kersten H. Can screening tools for potentially inappropriate prescriptions in older adults prevent serious adverse drug events? Eur J Clin Pharmacol. 2019;75:627–37.

Tables

Table 1

Characteristics of the Study Population

Number and Raw Percentage of Characteristics by Potentially Inappropriate Medication Use among Older Adults with Comorbid Diabetes and Hypertension
|                        | Total       | PIMs Use   | No PIMs Use | P value |
|------------------------|-------------|------------|-------------|---------|
|                        | N   | %   | N   | %   | N   | %   |         |
| Total                  | 1,853 | 100 | 1,039 | 56  | 814  | 44  |         |
| Age Mean(SD)           | 72(6.16) |    | 72(6.11) |    | 72(6.25) |    | 0.18    |
| Average number of      | 7(0.19) |    | 8(2.19) |    | 5(0.16) |    | <0.0001 |
| medications (SD)       |         |    |        |    |        |    |         |
| Average number of      | 3(2.8)  |    | 3(2.8) |    | 3(2.7) |    | <0.0001 |
| conditions (SD)        |         |    |        |    |        |    |         |
| Gender                 |          |    |        |    |        |    | 0.12    |
| Male                   | 710   | 38  | 382   | 54  | 328   | 46  |         |
| Female                 | 1,143 | 62  | 657   | 58  | 486   | 43  |         |
| Marital Status         |          |    |        |    |        |    | 0.08    |
| Single                 | 71    | 4   | 32    | 45  | 39    | 55  |         |
| Married                | 1,573 | 96  | 872   | 55  | 701   | 45  |         |
| Nationality            |          |    |        |    |        |    | 0.35    |
| Saudi                  | 1,728 | 93  | 965   | 56  | 763   | 44  |         |
| Non-Saudi              | 123   | 7   | 74    | 60  | 49    | 40  |         |
| Dyslipidemia           |          |    |        |    |        |    | 0.12    |
| Yes                    | 1,181 | 64  | 678   | 57  | 503   | 43  |         |
| No                     | 672   | 36  | 361   | 54  | 311   | 46  |         |
| IHD                    |          |    |        |    |        |    | 0.00    |
| Yes                    | 128   | 7   | 97    | 76  | 31    | 24  |         |
| No                     | 1,725 | 93  | 942   | 55  | 783   | 45  |         |
| Asthma                 |          |    |        |    |        |    | 0.34    |
| Yes                    | 194   | 11  | 115   | 59  | 79    | 41  |         |
| No                     | 1,659 | 90  | 924   | 56  | 735   | 44  |         |
| Osteoarthritis         |          |    |        |    |        |    | 0.18    |
| Yes                    | 179   | 10  | 92    | 51  | 87    | 49  |         |
| No                     | 1,674 | 90  | 947   | 57  | 727   | 43  |         |
| Osteoporosis           |          |    |        |    |        |    | 0.69    |
| Yes                    | 163   | 9   | 89    | 55  | 74    | 45  |         |
| No                     | 1,690 | 91  | 950   | 56  | 740   | 44  |         |
| Anxiety                |          |    |        |    |        |    | 0.00    |
| Yes                    | 126   | 7   | 99    | 79  | 27    | 21  |         |
| No                     | 1,727 | 93  | 940   | 54  | 787   | 46  |         |
| Depression             |          |    |        |    |        |    | 0.57    |
| Polypharmacy | Yes | No |
|--------------|-----|----|
|               | 26  | 1872 |
|               | 1   | 99  |
|               | 16  | 1023 |
|               | 62  | 56  |
|               | 10  | 804 |
|               | 39  | 44  |

Polypharmacy

| Polypharmacy | Yes | No |
|--------------|-----|----|
|               | 26  | 1872 |
|               | 1   | 99  |
|               | 16  | 1023 |
|               | 62  | 56  |
|               | 10  | 804 |
|               | 39  | 44  |

Polypharmacy

| Polypharmacy | Yes | No |
|--------------|-----|----|
| <=5          | 1558| 84 |
| 0 to 4 drugs | 957 | 61 |
|              | 601 | 39 |

Note: Study Population Comprised of 1,853 older adults, age 65 years and older, with comorbid diabetes and hypertension.

T-test was used to assess the association between age and number of medications and PIMs use.

IHD: Ischemic Heart Disease; N:Number; PIMs: Potentially Inappropriate Medications; Rx: Medications; Sig: Significance

Asterisks (*) represent significant differences in PIMs use, ***P< .001
Table 2
Summary of the Findings of Potentially Inappropriate Medications to Be Avoided For Most Older Adults According to the 2019 Beers criteria

| N | % |
|---|---|
| Average number of PIMs (SD) | 0.96 (0.86) |
| Average number of medications (SD) | 7.26 (3.16) |

Potentially Inappropriate Medications Use

|         |         |     |
|---------|---------|-----|
| Yes     | 1,039   | 56.1|
| No      | 814     | 43.9|

Number of Potentially Inappropriate Medications

| PIMs Use                  | N   | %  |
|---------------------------|-----|----|
| No PIM                    | 814 | 43.9|
| One PIM                   | 746 | 40.3|
| Two PIMs                  | 245 | 13.2|
| Three or more PIMs        | 48  | 2.6 |

Classification of most common PIMs prescribed

| PIMs Type                    | N   | %  |
|------------------------------|-----|----|
| Gastrointestinal             | 675 | 36.43|
| Endocrine                    | 535 | 28.87|
| Pain Medications (NSAIDs)    | 136 | 7.34 |
| Antidepressants              | 9   | 0.49 |
| Antispasmodics               | 8   | 0.43 |
| Antipsychotics               | 4   | 0.22 |
| Anti-infective               | 4   | 0.22 |
| Genitourinary                | 1   | 0.05 |
| Antiparkinsonian agents      | 1   | 0.05 |

Note: Study Population Comprised of 1,853 older adults, age 65 years and older, with comorbid diabetes and hypertension
N: Number; NSAIDs: Nonsteroidal anti-inflammatory drugs; PIMs: Potentially Inappropriate Medications
No use was reported for central or alpha blocker agents, first-generation antihistamines, antithrombotic, barbiturates, benzodiazepines, hypnotics, or skeletal muscle relaxants

Table 3
Adjusted Odds Ratios and 95% Confidence Intervals From Logistic Regression on PIM Use among Older Patients with Comorbid Diabetes and Hypertension

| PIMs Use                  | AOR | 95% CI       | Sig. |
|---------------------------|-----|--------------|------|
| Age                       | 1.01| [0.99-1.02]  |      |
| Gender                    |     |              |      |
| Male                      | 0.96| [0.77-1.21]  |      |
| Female (Ref.)             |     |              |      |
| Marital Status            |     |              |      |
|                         |     |               |
|-------------------------|-----|---------------|
|                         |     | [0.40-1.11]   |
| **Nationality**         |     |               |
| Single                  | 0.67|               |
| Married (Ref.)          |     |               |
| Saudi                   | 0.79| [0.52-1.20]   |
| Non-Saudi (Ref.)        |     |               |
| **Dyslipidemia**        |     |               |
| Yes                     | 1.1 | [0.88-1.38]   |
| No (Ref.)               |     |               |
| **IHD**                 |     |               |
| Yes                     | 2.12| [1.35-3.32] **|
| No (Ref.)               |     |               |
| **Asthma**              |     |               |
| Yes                     | 1.17| [0.83-1.64]   |
| No (Ref.)               |     |               |
| **Osteoarthritis**      |     |               |
| Yes                     | 0.75| [0.54-1.06]   |
| No (Ref.)               |     |               |
| **Osteoporosis**        |     |               |
| Yes                     | 0.92| [0.63-1.34]   |
| No (Ref.)               |     |               |
| **Anxiety**             |     |               |
| Yes                     | 3.08| [1.87-5.07] ***|
| No (Ref.)               |     |               |
| **Depression**          |     |               |
| Yes                     | 0.9 | [0.36-2.31]   |
| No (Ref.)               |     |               |
| **Polypharmacy**        |     |               |
| >=5                     | 4.14| [3.06-5.60] ***|
| 0 to 4 drugs (Ref.)    |     |               |

**Note:** Study Population Comprised of 1,853 older adults, age 65 years and older, with comorbid diabetes and hypertension. Reference group for PIMs was “No PIMs use” IHD: Ischemic Heart Disease; AOR: Adjusted Odds Ratio; PIMs: Potentially Inappropriate Medications; Ref: Reference group; Sig: Significance. Asterisks (*) represent significant differences in PIMs use

***P< .001; **.001 ≤ p ≤ .01